The influence of surface modified poly(L-lactic acid) films on the differentiation of human monocytes into macrophages by Correia, Clara R. et al.
Biomaterials
Science
PAPER
Cite this: Biomater. Sci., 2017, 5, 551
Received 16th December 2016,
Accepted 11th January 2017
DOI: 10.1039/c6bm00920d
rsc.li/biomaterials-science
The inﬂuence of surface modiﬁed poly(L-lactic
acid) ﬁlms on the diﬀerentiation of human
monocytes into macrophages†
Clara R. Correia,‡§a,b Joana Gaifem,§b,c Mariana B. Oliveira,‡a,b Ricardo Silvestre*b,c
and João F. Mano*‡a,b
Macrophages play a crucial role in the biological performance of biomaterials, as key factors in deﬁning
the optimal inﬂammation-healing balance towards tissue regeneration and implant integration. Here, we
investigate how diﬀerent surface modiﬁcations performed on poly(L-lactic acid) (PLLA) ﬁlms would
inﬂuence the diﬀerentiation of human monocytes into macrophages. We tested PLLA ﬁlms without
modiﬁcation, surface-modiﬁed by plasma treatment (pPLLA) or by combining plasma treatment with
diﬀerent coating materials, namely poly(L-lysine) and a series of proteins from the extracellular matrix:
collagen I, ﬁbronectin, vitronectin, laminin and albumin. While all the tested ﬁlms are non-cytotoxic,
diﬀerences in cell adhesion and morphology are observed. Monocyte-derived macrophages (MDM)
present a more rounded shape in non-modiﬁed ﬁlms, while a more elongated phenotype is observed
containing ﬁlopodia-like and podosome-like structures in all modiﬁed ﬁlms. No major diﬀerences are
found for the expression of HLA-DR+/CD80+ and CD206+/CD163+ surface markers, as well as for the
ability of MDM to phagocytize. Interestingly, MDM diﬀerentiated on pPLLA present the highest expression
of MMP9. Upon diﬀerentiation, MDM in all surface modiﬁed ﬁlms present lower amounts of IL-6 and
IL-10 compared to non-modiﬁed ﬁlms. After stimulating MDM with the potent pro-inﬂammatory agent
LPS, pPLLA and poly(L-lysine) and ﬁbronectin-modiﬁed ﬁlms reveal a signiﬁcant reduction in IL-6
secretion, while the opposite eﬀect is observed with IL-10. Of note, in comparison to non-modiﬁed ﬁlms,
all surface modiﬁed ﬁlms induce a signiﬁcant reduction of the IL-6/IL-10 ratio, a valuable prognosticator
of the pro- versus anti-inﬂammatory balance. These ﬁndings provide important insights into MDM–bio-
material interactions, while strengthening the need for designing immune-informed biomaterials.
Introduction
Biodegradable polymers are commonly used in biomedical
applications, including the development of surgical implants,
drug delivery systems and tissue engineering constructs.1
Materials targeting organ substitution with permanent func-
tions in the body are usually preferred to show high inertness,
associated with the concept of biotolerability.2 Oppositely, bio-
degradable polymers aiming at tissue regeneration must show
an interplay with the implantation environment.3,4
One of the most important characteristics of biomaterials is
their ability to trigger adequate levels of host inflammatory
responses. An exacerbated inflammatory response leads to
abnormal tissue healing, characterized by chronic inflam-
mation, fibrotic encapsulation, and scar tissue formation.
These events ultimately promote the rejection of the implanted
biomaterial.5,6 On the other hand, the innate inflammatory
process followed by the implantation of a biomaterial is also a
keystone for eﬃcient tissue regeneration and repair.7,8
Therefore, designing biomaterial-based therapies that have the
ability to modulate the inflammatory response must be
accompanied by the understanding of biomaterial–immune
system interactions.
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Inflammation is an extremely complex multistage process
involving numerous cell types and mediator signals.9 In
particular, macrophages (Mφ) play an important role in wound
healing and biomaterial-mediated inflammation. Immediately
after implantation, monocytes are recruited from peripheral
blood to the implantation site where they diﬀerentiate into
Mφ. Inflammatory signals from the tissue injury around the
implanted biomaterial mediate the diﬀerentiation of mono-
cytes into inflammatory Mφ via autocrine and paracrine signal-
ling.10 In the early stages of inflammation, Mφ attempt to
remove the foreign body via phagocytosis and secrete large
amounts of bioactive mediators, such as (i) reactive oxygen
species to degrade the biomaterial, (ii) chemokines to direct
additional inflammatory cells to the site of injury, and (iii)
cytokines to further activate the surrounding inflammatory
cells.11,12 If the inflammatory response is not excessive, Mφ
enable the injured site to move into the healing phase by releas-
ing growth factors that promote the proliferation of fibroblasts
and blood vessel formation.13 Mφ may present a wide plethora
of phenotypes with inflammatory or anti-inflammatory/regener-
ation-adjuvant features.14 The states of ‘functionally active’ Mφ
phenotypes, with upregulation of both pro- and anti-inflamma-
tory markers have been reported as eﬃcient in modulating the
integration of biomaterials.15 The classic and alternative acti-
vation of Mφ are also termed M1 and M2 to mimic the T helper
(Th) cell nomenclature. While the classically activated (M1)
enhances Th1 type inflammation,16 the alternatively activated
(M2) enhances the Th2 response and improve tissue
healing.16,17 Physical properties such as substrate stiﬀness, topo-
graphy, pore size and the size of wear debris; chemical pro-
perties such as surface chemistry, ligand presentation and the
release of growth factors; and temporal properties, such as
degradation rates, all influence the monocyte-to-macrophage
diﬀerentiation and activation as well as their cytokine
secretion.9,14,18–23 With this in mind, a new generation of bioma-
terials is being designed in an attempt to control the immune
response of the body after implantation. The idea is to tailor the
phenotype and physiology of Mφ, and thus ultimately guide
them into an appropriate stimulus towards tissue regeneration.
PLLA is a biodegradable thermoplastic aliphatic polyester
derived from the polymerization of L-lactide in lactic acid.24
Polyesters have been well documented for their excellent bio-
degradability, biocompatibility, nontoxicity and their biocompati-
ble degradation products. However, poor hydrophilicity and the
lack of natural recognition sites on polyester surfaces for covalent
cell-recognition signal molecules to promote cell attachment are
the main drawbacks of PLLA as tissue engineering bio-
materials.25,26 Therefore, diﬀerent techniques have been pro-
posed to modify its surface to enhance cell–material interactions.
Plasma treatment is one of the most widely used treatment
techniques for improving the surface properties of polymers
for use in Tissue Engineering and Regenerative Medicine
(TERM).27 The principle is based on the presence of free elec-
trons in the air, which are accelerated by a high voltage dis-
charge and ionize the gas. As a result, chemical and physical
modifications occur on the modified surfaces, creating reactive
sites such as amine and carboxyl groups.24,28,29 Despite the
use of polyester biomaterials in clinical practice, only a few
studies addressed their immunomodulatory eﬀects.9,30,31
In this context, we aim to study the interaction of surface-
modified PLLA films with human monocyte-derived macro-
phages (MDM). We aim to assess how diﬀerent surface modifi-
cations performed on PLLA films would influence the diﬀeren-
tiation of human monocytes into Mφ and their phenotypic
polarization and activation profiles. To this end, films were
produced and tested without modification (PLLA) or after
diﬀerent surface modifications known to enhance cell
adhesion. The surface of such films was modified by employ-
ing air-plasma technology (pPLLA) or by combining air-
plasma with diﬀerent coating materials, namely poly(L-lysine)
(pPLLA-PLL) and various extracellular matrix (ECM)-derived
proteins, namely collagen I (pPLLA-COLL I), fibronectin
(pPLLA-FN), vitronectin (pPLLA-VTN), laminin (pPLLA-LAM)
and albumin (pPLLA-ALB). MDM were characterized regarding
their morphology, surface markers, and cytokine secretion.
Moreover, an additional pro-inflammatory stimulus was added
with a lipopolysaccharide (LPS) and the resultant cytokine
profile was evaluated.
Experimental
PLLA film production
PLLA films were produced by the solvent casting methodology.
Briefly, PLLA (5% w/v, Mw ∼ 1600–2400, 70% crystallinity,
Polysciences) dissolved in methylene chloride (Fisher
Chemical) was poured to a glass Petri dish. The solvent was
left to evaporate overnight at room temperature (RT) inside a
fume hood. Afterwards, the produced PLLA films were cut into
disks to obtain films with 1 cm2.
Plasma surface modification
The plasma-treatment of PLLA was performed according to our
previously described protocol.32 Briefly, PLLA films were
placed in a plasma reactor chamber (PlasmaPrep5, Gala
Instrumente) fitted with a radio frequency generator. Air was
used as the working atmosphere to generate a glow discharge
plasma at 0.2 mbar and 30 V for 15 min. Films were placed
vertically to allow plasma treatment on both sides.
Coating materials
The adsorption of the diﬀerent coating materials was per-
formed following the respective commercially available proto-
cols. Following plasma treatment, PLLA films were immedi-
ately sterilized by immersion in 70% v/v ethanol for 2 h at RT.
After washing with phosphate-buﬀered saline (PBS, Sigma-
Aldrich), the films were immersed in the diﬀerent coating
solutions, namely collagen I (8 µg cm−2, collagen from human
placenta, Bornstein and Traub type I, Sigma-Aldrich),
poly(L-lysine) (2 µg cm−2, poly-L-lysine hydrobromide, Mw =
30 000–70 000, Sigma-Aldrich), fibronectin (3 µg cm−2, human
plasma fibronectin purified protein, Merck Millipore),
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vitronectin (0.1 µg cm−2, vitronectin from human plasma,
Sigma-Aldrich), laminin (2 µg cm−2, laminin from human
placenta, Sigma-Aldrich) and albumin (4 µg cm−2, albumin
solution human 30% in 0.85% sodium chloride, Sigma-
Aldrich). PLLA films were incubated with each coating solution
for 2 h at 37 °C and then at 4 °C overnight.
Isolation of blood-derived monocytes and in vitro
diﬀerentiation into macrophages
Experiments were conducted using buﬀy coats from healthy
donors (n = 7) supplied by the Hospital of Braga, after approval
of the Competent Ethics Committee (CEC). The human
samples received were handled in accordance with the guide-
lines approved by the CEC. All the donors agreed and signed
an authorized consent (ethical approval reference SECVF014/
2015).
Monocytes were isolated from the buﬀy coats of healthy
donors by centrifugation using Histopaque®-1077 (Sigma-
Aldrich) followed by immunomagnetic separation with the
human anti-CD14 purification kit (Miltenyi Biotec). The purity
of the separation was always confirmed by flow cytometry and
was superior to 95% (Fig. SI1†). Purified monocytes were
diﬀerentiated in vitro into MDM in the diﬀerent PLLA films,
namely without modification, plasma-treated, or combining
plasma treatment with various coating materials. Cells were
cultured above the films in RPMI 1640 medium containing
heat-inactivated fetal bovine serum (10%, FBS, Gibco),
L-glutamine (2 mM, Gibco), penicillin (50 U mL−1, Gibco),
streptomycin (50 µg mL−1, Gibco) and HEPES (10 mM, Gibco),
and supplemented with the human macrophage colony stimu-
lating factor (20 ng mL−1, M-CSF, Peprotech) for 7 days at
37 °C under a humidified 5% CO2 air atmosphere. The
medium was renewed on the third day of culture. MDM cul-
tured in modified and non-modified PLLA films were sup-
plemented with LPS (100 ng mL−1, Sigma-Aldrich) for 24 hours
at 37 °C under a humidified 5% CO2 air atmosphere. Positive
controls for surface marker analysis were obtained by polariz-
ing macrophages with 10 ng mL−1 of LPS (Sigma-Aldrich) plus
100 U mL−1 of IFN-ϒ (Peprotech) for M1 and with 20 ng mL−1
of IL-4 (Peprotech) for M2.
Cell quantification
The amount of adhered cells after 7 days of culture at the
surface of PLLA films was quantified by image analysis. The
samples were fixed with 10% v/v formalin (BD Biosciences) for
30 min at RT. Upon PBS washing, 500 µL of PBS containing
0.5 µL DAPI (1 mg mL−1, 4,6-diaminidino-2-phenylindole-
dilactate, Sigma-Aldrich) was added to each sample.
Ultimately, the samples were washed with PBS and visualized
by fluorescence microscopy (Axioimage RZ1M, Zeiss,
Germany). The total cell number was quantified by counting
the number of stained nuclei in PLLA films (for each biomater-
ial formulation, 3 replicates were analyzed per donor; n = 4)
using ImageJ software (NIH, USA). Five images per film were
used for the quantification.
Phalloidin/DAPI fluorescence staining
In order to observe the cellular morphology, MDM were
stained for actin and nuclei. After 7 days of culture, the
samples were fixed with 10% v/v formalin (BD Biosciences)
for 30 min followed by permeabilization with 0.1% v/v Triton-
X (Sigma-Aldrich) for 5 min, both at RT. Upon PBS washing,
500 µL of PBS containing 10 µL phalloidin (50 µg mL−1, phal-
loidin tetramethylrhodamine B isothiocyanate, Sigma-
Aldrich) was added to each sample. After 1 h at RT, the
samples were washed with PBS and counterstained with DAPI
by immersing the samples in 500 µL of PBS containing 0.5 µL
DAPI (1 mg mL−1, 4,6-diaminidino-2-phenylindole-dilactate,
Sigma-Aldrich). Ultimately, the samples were washed with
PBS and visualized by fluorescence microscopy (Axioimage
RZ1M, Zeiss, Germany). Z-Stack mode was used with a resolu-
tion of 5 µm between the slides by using the AxioVision
software.
Live–dead assay
To assess the viability of MDM in contact with PLLA films,
a live–dead assay was performed using calcein-AM and
propidium iodide dyes. Briefly, 1 mL of PBS containing
2 μL of calcein-AM (1 mg mL−1, Invitrogen) and 1 μL of PI
(1 mg mL−1, Invitrogen) was added to each well. The samples
were then incubated at 37 °C for 10 min protected from light.
Afterward, the samples were washed with PBS and immediately
visualized by fluorescence microscopy (Axioimage RZ1M,
Zeiss, Germany).
Scanning electron microscopy
The morphology of the MDM adhered at the surface of the
PLLA films was analyzed by scanning electron microscopy
(SEM). After 7 days of culture, the samples were fixed with 10%
v/v formalin (BD Biosciences) for 30 min and subsequently de-
hydrated using sequential ethanol series (60, 70, 80, 90, 96,
and 100%, 10 min each). The samples were gold-sputtered and
visualized (Leica Cambridge S-360) operating at 15.0 kV accel-
erating voltage.
Surface staining and phagocytic activity of monocyte-derived
macrophages
For analysis, MDM were detached from the PLLA films by incu-
bation with TrypLE™ Express solution (Life Technologies) at
37 °C for 10 min. For the analysis of surface markers, MDM
were incubated for 20 minutes with saturating concentrations
of monoclonal antibodies against HLA-DR (clone L243,
Biolegend), CD80 (clone 2D10, Biolegend), CD206 (clone 15–2,
Biolegend) and CD163 (clone GHI/61, Biolegend). To assess
the phagocytic activity, fluorescent yellow-green latex beads
(1.0 µm mean particle size, Sigma-Aldrich) were incubated
with Mφ at a 1 : 10 (cell/beads) ratio for 45 min or 4 hours at
37 °C. Before acquisition, the cells were washed with FACS
buﬀer (PBS with 2% FBS) to remove non-phagocytized beads.
The samples were acquired on a LSRII flow cytometer with
FACS Diva software (BD Biosciences). All data were analyzed
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using FlowJo v10 software (TreeStar Inc., Ashland, USA).
Fig. SI2† depicts the gating strategy for the characterization of
macrophage surface markers.
Protein quantification
TNF-α, IL-6, and IL-10 concentrations in the supernatants of
diﬀerentiated and/or LPS-treated MDM were determined by
ELISA using commercially available kits (Biolegend) according
to the manufacturer’s instructions. Results are shown as arbi-
trary units (AU), calculated as follows: [cytokine (pg µL−1)/
number of cells] × 1000.
Quantitative real-time polymerase chain reaction (qPCR)
Total RNA from cultured macrophages was extracted with the
TripleXtractor reagent (Grisp) according to the manufacturer’s
instructions. cDNA was synthesized using a GRS cDNA
Synthesis MasterMix (Grisp) for reverse-transcription PCR.
Target gene mRNA expression was quantified in 20 ng of cDNA
by real-time PCR (Bio-Rad CFX96 Real-Time System C1000
Thermal Cycler) using a KAPA SYBR® FAST qPCR kit Master
Mix (KAPA Biosystems) and normalized to the Gapdh and
β-actin mRNA levels. Specific oligonucleotides for Mmp9 are
(forward) TGT ACC GCT ATG GTT ACA CTC G, (reverse) GGC
AGG GAC AGT TGC TTC T; for Mmp12 are (forward) GAT CCA
AAG GCC GTA ATG TTC C, (reverse) TGA ATG CCA CGT ATG
TCA TCA G; for Gapdh are (forward) AAG GTG AAG GTC GGA
GTC AAC, (reverse) GGG GTC ATT GAT GGC AAC AAT A; and
for β-actin are (forward) GCC GTC TTC CCC TCC ATC GTG,
(reverse) GGA GCC ACA CGC AGC TCA TTG TAG A.
Statistical analysis
Data are shown as mean ± standard deviation or mean ± SEM
from at least four donors. Statistical analyses were performed
using the one-way ANOVA test with Tukey’s multiple-compari-
son post-test for multiple group comparisons.
Results and discussion
It is well established that microenvironmental cues presented
by biomaterials play a crucial role in modulating the immune
cell response.33 While much progress has been made in under-
standing these eﬀects on both somatic34 and stem34,35 cells,
the eﬀect of such biophysical and biochemical signals on
immune cells, specifically Mφ, is less well known. To fulfill
their plethora of functions, Mφ exhibit a spectrum of transient
polarization states that are influenced by varying micro-
environmental cues, some of which may be biomaterial-
based.14 This deficit in understanding the macrophage–
biomaterial interaction led us to study the interplay between
the human monocytes during their diﬀerentiation process into
macrophages with PLLA, a widely used biomaterial in TERM
applications.
After isolation, monocytes were immediately cultured on
the surface of PLLA films with or without diﬀerent surface
modifications. After 7 days of diﬀerentiation, the amount of
adhered Mφ per film was quantified. As shown in Fig. 1A,
PLLA films without modification presented the lowest number
of cells. This diﬀerence was highly significant when comparing
non-modified with plasma-modified films (pPLLA). Although
with a lower significance, plasma-modified films combined
with vitronectin (pPLLA-VTN) or laminin (pPLLA-LMN) coat-
ings also showed a significantly lower number of adhered cells
compared to pPLLA. In fact, the low hydrophilicity and lack of
natural recognition sites for cell adhesion are well-known
major drawbacks of PLLA for TERM applications.25,26 The
treatment of the PLLA surface with plasma modification allows
the increase of the hydrophilicity of PLLA.36 Consequently, the
binding strength and structural arrangement of water mole-
cules at the surface of PLLA are increased, aﬀecting protein–
surface interactions.24 Indeed, protein adsorption to surfaces
with diﬀerent chemistries has been shown to aﬀect Mφ
adhesion and morphology.22 Therefore, the adsorption of
serum proteins from the culture medium to the surface of
pPLLA might have also contributed to the highest MDM
adhesion. The presence of serum in the culture medium also
allowed the study of MDM behavior in a closer environment to
what occurs in vivo following implantation, in which serum
proteins adsorb to the surface of the implant within seconds.
A transient surface matrix is then formed, and, after activation
of the coagulation cascade and complement systems, diﬀerent
cell populations are activated following thrombus formation.37
Among a series of cellular events, Mφ cells adhere to the
surface of the implant and develop a response.12,38 In
addition, coating PLLA films with PLL, well known to improve
cell adhesion, or with ECM-derived proteins also contributed
to higher MDM adhesion compared to non-modified PLLA,
since their presence improve the surface recognition by
MDM.39,40 Importantly, all tested PLLA surfaces were non-
toxic, as shown by the higher ratios of living cells in the live–
dead staining assay (Fig. SI3†). The morphologies of MDM in
contact with diﬀerent PLLA surfaces were further observed by
F-actin staining (Fig. 1B). Fluorescence microscopy obser-
vations demonstrated distinct MDM morphologies upon diﬀer-
entiation in the presence of diﬀerent PLLA surfaces. While
non-modified PLLA films revealed the presence of rounded
MDM, in the other formulations a heterogenic population
composed by more elongated MDM with a higher surface area
was observed. In addition, in all surface modified films, MDM
exhibited more filopodia-like and podosome-like structures,
which are involved in cell motility and adhesion, respectively,
compared to non-modified PLLA. A more detailed observation
of the MDM morphologies could be confirmed by SEM ana-
lysis, corroborating the actin-staining results (Fig. 1C). Overall,
these results show that the diﬀerent surface modifications of
PLLA films aﬀected MDM adhesion and morphology during
monocyte-to-macrophage diﬀerentiation.
The expression profile of surface markers and cytokine
secretion of MDM diﬀerentiated in diﬀerent surface-modified
PLLA films was assessed. The phenotypical profile of MDM
diﬀerentiated in non-modified PLLA films or after surface
modification by plasma treatment alone or combined with
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Fig. 1 Quantiﬁcation and morphology of human monocyte-derived macrophages (MDM) diﬀerentiated in PLLA ﬁlms after 7 days of culture. Cells
were diﬀerentiated in ﬁlms without treatment (PLLA), subjected to air-plasma treatment (pPLLA) or with additional coatings, namely collagen I
(pPLLA-COLL-l), poly(L-lysine) (pPLLA-PLL), ﬁbronectin (pPLLA-FN), vitronectin (pPLLA-VTN), laminin (pPLLA-LMN), and albumin (pPLLA-ALB).
(A) Quantiﬁcation of cell nuclei by image analysis after DAPI staining. Results are shown as mean ± SD (*p < 0.05 and ****p < 0.0001). (B) Actin
polymerization by phalloidin ﬂuorescence staining. Cell nuclei are counterstained in blue with DAPI. Scale bars are 50 µm. (C) SEM images
evidencing the diﬀerent morphologies of MDM in contact with the diﬀerent surfaces of PLLA ﬁlms. Scale bars are 10 µm.
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diﬀerent coating materials was characterized by the expression
of specific cell surface markers by flow cytometry. No major
diﬀerences were found in the expression of the well-known
classically activated (M1) markers HLA-DR+CD80+, when com-
paring the percentage of positive cells under the several con-
ditions of diﬀerentiation (Fig. 2A and B). Similar results were
observed for the proportion of the alternatively activated (M2)
markers CD163+CD206+ (Fig. 2A and B).41 Moreover, no diﬀer-
ences were observed when comparing the mean fluorescence
intensity (MFI) of each one of the cell surface markers in MDM
diﬀerentiated in the diverse PLLA films (Table 1). These results
indicate that the diﬀerent surface modifications performed on
PLLA films did not significantly impact the phenotype of Mφ
during the diﬀerentiation process.
In order to dissect the potential functional alterations in
Mφ due to the biomaterial composition, we further character-
Fig. 2 (A and B) Cell surface expression of CD163, CD206, HLA-DR, and CD80 in human monocyte-derived macrophages (MDM) diﬀerentiated in
ﬁlms without modiﬁcation (PLLA), modiﬁed by plasma treatment (pPLLA), or modiﬁed combining plasma treatment with diﬀerent coating materials,
namely collagen I (pPLLA-COLL-I), poly(L-lysine) (pPLLA-PLL), ﬁbronectin (pPLLA-FN), vitronectin (pPLLA-VTN), laminin (pPLLA-LMN), or albumin
(pPLLA-ALB). (C) Phagocytic activity of MDM diﬀerentiated in each ﬁlm evaluated by the co-incubation with ﬂuorescent latex-beads for 45 minutes
or 4 hours. The percentage of phagocytized beads was quantiﬁed by ﬂow cytometry. (D) qPCR quantiﬁcation of the transcriptional levels of MMP9
and MMP12. The nomenclature “cycles over housekeeping” corresponds to the diﬀerence between the cycle threshold (CT) of the tested gene and
the housekeeping gene. (E) IL-6, TNF-α and IL-10 secretion quantiﬁcation by the ELISA assay. (F) IL-6, TNF-α and IL-10 secretion quantiﬁcation by
the ELISA assay after an additional stimulation for 24 h with LPS. (G) IL-6/IL-10 ratio before and after LPS stimulation. In (E) and (F), statistical analysis
is relative to non-modiﬁed ﬁlms (PLLA condition) and cytokine quantiﬁcations are shown as arbitrary units (AU). In (G) the symbol # represents sig-
niﬁcant diﬀerences p < 0.005 between PLLA and pPLLA or PLLA and pPLLA-PLL. The *p < 0.05 relates to the signiﬁcant diﬀerence between PLLA
and all the other tested conditions. Mean ± SD are from at least four diﬀerent donors (*p < 0.05, **p < 0.005, ***p < 0.001 and ****p < 0.0001).
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ized the eﬀector functions of these cells. The percentage of
phagocytosis was evaluated by flow cytometry in two distinct
periods of contact with the latex beads. We observed that
MDM maintained the same ability to phagocytize, since the
percentage of phagocytized beads is similar under all con-
ditions, independent of the period of contact (Fig. 2C). We
further evaluated the expression of genes involved in ECM
organization such as matrix metalloproteinases (MMPs) as this
family of enzymes is known to regulate various inflammatory
and repair processes.42 In particular, MMP9 is known to
induce extracellular matrix remodelling,43 while MMP12 is
expressed by pro-healing macrophages.44 We observed that Mφ
diﬀerentiated in films modified with plasma (pPLLA) had the
highest expression of MMP9, with a significant diﬀerence
when compared with those diﬀerentiated in non-modified
PLLA films and with collagen I-coated films (pPLLA-COLL-I).
No significant alterations between the expression levels of
MMP12 were observed (Fig. 2D). This result in part reveals the
specificity of surface modifications on films in modulating
macrophage MMP’s expression, confirming previous studies
that demonstrate the biomaterial-dependent eﬀect on
MMPs.45,46 Although the significance was restricted to pPLLA,
the increase in MMP9 expression can reflect an eﬀect of
plasma treatment alone to predispose MDM towards alterna-
tive activation given that the production and activity of MMP9
were described higher in M2 macrophages.47 Moreover, MMP9
was shown to be required for tissue remodeling in distinct
settings,48–50 acting also as a strong angiogenic factor.43 Our
data suggests that the distinct coating materials may hinder
the transcription upregulation conferred by plasma treatment
alone. Future studies will shed light on the correlation
between the increasing MMP9 transcript levels and the surface
modifications upon plasma treatment.
The ability of Mφ to secrete a wide array of inflammatory
mediators in response to external signals such as cytokines is
well described in the literature.9,21,22,51,52 We determined the
cytokine profile of MDM during diﬀerentiation when cultured
in contact with diﬀerent surface modified PLLA films. The
secretions of tumor necrosis factor (TNF)-α, and interleukins
(IL)-6 and -10 were analyzed. TNF-α and IL-6 are pro-inflamma-
tory cytokines commonly analyzed when studying the inflam-
matory response induced by biomaterials.9,53 IL-10 is one of
the most studied anti-inflammatory cytokines, and is crucial
in restraining inflammation.54 Results show that MDM diﬀer-
entiated in almost all surface-modified films produced signifi-
cantly lower amounts not only of the pro-inflammatory cyto-
kine IL-6 but also of the anti-inflammatory cytokine IL-10,
when compared with non-modified PLLA films. The secretion
profile of TNF-α followed the same trend, although without
statistical significance. Exceptionally, no significant diﬀer-
ences were found in the secretion profile of IL-6 secretion
when comparing laminin-modified films (pPLLA-LMN) with
non-modified films. These results evidenced the tailoring role
of surface modified films, leading to lower secretions of pro-
and anti-inflammatory cytokines compared to non-modified
films (Fig. 2E).Ta
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To further understand whether the diﬀerentiated response
observed using diﬀerent surface modified PLLA films would
be maintained after stimulation with external factors, MDM
were treated with LPS, a well-known pro-inflammatory stimu-
lus. Subsequently, the secretions of TNF-α, IL-6, and IL-10 were
again quantified.
Our results suggest that MDM stimulated in several surface
modified films showed a lower IL-6 secretion when compared
with non-modified films (Fig. 2F). In particular, pPLLA,
pPLLA-PLL, and pPLLA-FN films showed a significantly lower
IL-6 secretion when compared with non-modified films.
Remarkably, after the pro-inflammatory LPS stimulation, IL-10
secretion in all surface-modified films was higher compared to
non-modified films. These findings were statistically signifi-
cant for pPLLA and pPLLA-FN films. Again, no significant
diﬀerences could be observed for TNF-α secretion.
The IL-6/IL-10 ratio has been used in distinct experimental
settings as a valuable prognosticator of the pro- versus anti-
inflammatory balance.55–58 The increased IL-6/IL-10 ratio was
significantly associated in favor of pro-inflammatory responses
even in cases with similar TNF-α and IL-1β levels.55,58
Remarkably, while the IL-6/IL-10 ratio (Fig. 2G) remained
similar upon Mφ diﬀerentiation in all the films tested, a strik-
ing decrease could be observed upon LPS stimulation in all
surface-modified films. This was in clear contrast with Mφ
diﬀerentiated in non-modified films, in which a 9-fold
increase of the IL-6/IL-10 ratio was observed. Further pieces of
experimental evidence support the anti-inflammatory potential
of MDM diﬀerentiated in surface-modified films. After evalu-
ation of the MFI levels of classical and alternative markers,
recent studies demonstrate that M2 macrophages present high
surface levels of CD163, while maintaining the CD80
expression low. An opposite trend was observed for
M1 macrophages.41,59 Accordingly, Mφ diﬀerentiated in all
surface-modified films presented a phenotype closer to
M2 macrophages in terms of the CD163 and CD80 surface
MFI, although no significant diﬀerences were found for all the
films tested (Table 1). In agreement with our data, previous
studies on the macrophage–biomaterial interaction have relied
on the release of the immunoregulatory cytokine IL-10 and
CD163 expression, to specifically characterize an M2 and anti-
inflammatory polarization.60–62 Overall, the study of the cyto-
kine and surface marker profile in the present work suggests
that all surface-modified films contributed to a lower inflam-
matory response of MDM in comparison to non-modified
PLLA films. This ability was particularly distinct after the pro-
inflammatory LPS stimulation. These data provide important
insights into the interaction of MDM with diﬀerent surface-
modified PLLA films. Most importantly, this study also
reinforced the idea that the Mφ phenotype occupies a conti-
nuum between M1 and M2 designations, thus expressing and
releasing both pro- and anti-inflammatory markers and cyto-
kines, as it has been suggested in other studies.9,37,63,64
Therefore, more than classifying monocyte/macrophage
populations in contact with biomaterials in a “bipolar classifi-
cation”, the well-known M1/M2 paradigm, our focus was
mainly to understand which functional responses of MDM in
their diﬀerentiation were being stimulated by their inter-
actions with diﬀerent surface-modified PLLA films. The induc-
tion of “functional” phenotypes of Mφ, which do not fit in the
conventional M1 or M2 phenotype classifications, has been
reported in diﬀerent sites of the fibrotic capsules elicited by
the implantation of biomaterials with diﬀerent pore sizes.15
One may speculate that such intermediate Mφ phenotypes
may be valuable to induce a balanced regeneration of tissues,
avoiding the triggering of excessive implant rejection associ-
ated with the M1 phenotype or excessive angiogenesis pro-
moted by the M2 phenotype. These results reinforce the need
to study the role of these simultaneously pro- and anti-inflam-
matory Mφ in the healing process.
The study presented herein rendered valuable conclusions
about the modulation eﬀect of diﬀerent surface-modified
PLLA films on the diﬀerentiation of MDM. Most importantly,
plasma-modification alone or combined with various coating
materials showed to be able to restrain the pro-inflammatory
character of non-modified films. In addition, although all
coating materials showed anti-inflammatory potential, they
did not elicit the secretion of pro-inflammatory cytokines. This
highlights the potential of such surface modifications to be
used as pro-healing biomaterials. The surface of biomaterials
is commonly modified with ECM-derived proteins to improve
not only cell adhesion but also to function as biomimetic sub-
strates. For example, the use of collagen I has been reported
for bone regeneration strategies,65 and laminin for neural
tissue engineering66 or combined with vitronectin for human
pluripotent stem cell expansion.67 The integration of the
output of these studies with the data presented herein
suggests that the proposed surface modifications of PLLA
films are amenable to be used as biomimetic coatings, while
avoiding an excessive pro-inflammatory response of MDM.
Therefore, it may be a promising strategy to extrapolate such
surface modifications to other biomaterials, seeking the
improvement of their biotolerability.
The findings obtained within this work contributed to
increase the knowledge about the interaction of human Mφ
with the widely used PLLA biomaterial, and also how diﬀerent
surface modifications can aﬀect this dynamic interaction.
Conclusions
Insights into macrophage–biomaterial biology and an
improved understanding of other components of the immune
system are required to establish a set of design principles that
aid in the engineering of a new generation of immuno-
informed biomaterials that can actively direct the innate
immune system. With this in mind, we demonstrated how
human MDM interact with PLLA films presenting diﬀerent
surface modifications. Overall, surface-modified PLLA films
disrupt the balance of macrophage polarization towards a
favorable anti-inflammatory profile, particularly when facing
an inflammatory stimulus. These results clearly demonstrate
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the complexity of the interplay of biomaterials and the
immune response. This urge for the performance of more
studies addressing this dynamic interaction, which are
expected to provide insight into the selection and design of
biomaterials based on how their chemistry, surface properties,
geometry, and other features will impact on the know-how
about the immunological system response. The “ideal”
response and cytokine environment remain uncertain, and
more complex studies are required to mimic more closely an
implantation scenario (e.g. diﬀerent immune cells combined
with other cell types involved in the healing process).
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